Close Menu

depression

NEW YORK (GenomeWeb) – Neuropsychiatric molecular diagnostics firm Assurex today said that it has secured a $25 million credit facility and $7 million in investments.
The funds will be used to increase clinical adoption of the Mason, Ohio-based firm's GeneSight products.

NEW YORK (GenomeWeb News) – Genomind, a firm developing genetic tests focused on psychiatry and neurology, announced today the closing of a $5 million financing round.

The National Institutes of Health this month awarded more than $400,000 in grant funding to support three research projects examining microRNAs in breast cancer, leukemia, and depression.

Despite initial setbacks, Myriad Genetics is moving ahead with development of protein biomarker panels for a variety of psychiatric disorders.

NEW YORK (GenomeWeb News) – Sundance Diagnostics today announced an exclusive, worldwide licensing deal with the Max Planck Institute of Psychiatry aimed at developing and commercializing a genetic test for predicting the risk of suicide from use of antidepressants.

NEW YORK (GenomeWeb News) – Investigators at Hartford Hospital's Genetics Research Center and Institute of Living will use a nearly $1.3 million federal grant to study the use of pharmacogenomic approaches in choosing medications for psychiatric patients.

Researchers from Assurex Health and the Mayo Clinic have jointly published data in Pharmacogenetics and Genomics showing that when doctors used the GeneSight pharmacogenomic test to personalize depression treatment for patients they experienced a greater decrease in depr

Ridge Diagnostics this week announced the launch of its MDDScore product, a proteomic test for aiding diagnosis of major depressive disorder.

Roughly one year after securing €5 million ($6.5 million) in venture capital funding, Spanish oligonucleotide drug developer nLife Therapeutics has set its sights on initiating non-human primate testing of its core intranasal delivery technology, which it hopes will spur licensin

SAN FRANCISCO (GenomeWeb News) – Researchers based in the Netherlands and elsewhere are relying on whole-exome sequencing in an isolated population in that country to help track down rare variants associated with complex diseases.

Pages

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.